| Retraction notice to: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody [Cancer Lett. 357 374-383]. | |
| Hu, Shi; Dai, Haibin; Zhang, Tiancheng; Fu, Wenyan; Berezov, Sandra D.; Chen, Cheng; Jorissen, Daniel; Takeda, Hiroaki; Bethune, Augus N. | |
| 刊名 | Cancer Letters (CANCER LETT)
 |
| 2017 | |
| 卷号 | Vol.401页码:81 |
| ISSN号 | 0304-3835 |
| URL标识 | 查看原文 |
| 内容类型 | 期刊论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/2929304 |
| 专题 | 天津大学 |
| 作者单位 | Translational Medicine Research Institute and International Joint Cancer Institute, The Second Military Medical University, Shanghai 200433, China Cancer Center, PLA General Hospital, PLA Postgraduate School of Medicine, 28 Fuxing Road, Beijing 100853, China Asian-Pacific Biosignatures Center, Tianjin Joint Academy of Biomedicine and Technology, Tianjin 300457, China Department of Anesthesiology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing 210002, China School of Life Sciences, Tianjin University, Tianjin 300072, China Molecular Drug Discovery Center, Xi'an Jinwa Pharmaceutical Co., Ltd, Xi'an, Shaanxi 710000, China |
| 推荐引用方式 GB/T 7714 | Hu, Shi,Dai, Haibin,Zhang, Tiancheng,et al. Retraction notice to: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody [Cancer Lett. 357 374-383].[J]. Cancer Letters (CANCER LETT),2017,Vol.401:81. |
| APA | Hu, Shi.,Dai, Haibin.,Zhang, Tiancheng.,Fu, Wenyan.,Berezov, Sandra D..,...&Bethune, Augus N..(2017).Retraction notice to: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody [Cancer Lett. 357 374-383]..Cancer Letters (CANCER LETT),Vol.401,81. |
| MLA | Hu, Shi,et al."Retraction notice to: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody [Cancer Lett. 357 374-383].".Cancer Letters (CANCER LETT) Vol.401(2017):81. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论